Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis

Publisher： Karger

E-ISSN： 1421-9832|230|1|46-54

ISSN： 1018-8665

Source： Dermatology, Vol.230, Iss.1, 2015-01, pp. : 46-54

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mild Cognitive Impairment in Patients with Moderate to Severe Chronic Plaque Psoriasis

By  

Dermatology, Vol. 228, Iss. 1, 2014-01 ,pp. : 78-85

Karger

Access to resources Recommend Favorite

What Happened after the Clinical Trials: Long-Term Safety and Efficacy of Ustekinumab in Daily Clinical Practice

By  

Dermatology, Vol. 229, Iss. 4, 2014-11 ,pp. : 324-332

Karger

Access to resources Recommend Favorite

Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis

By  

Dermatology, Vol. 219, Iss. 3, 2009-08 ,pp. : 209-218

Karger

Access to resources Recommend Favorite

Patients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation of Efalizumab Suspension

By  

Dermatology, Vol. 222, Iss. 3, 2011-04 ,pp. : 250-255

Karger

Access to resources Recommend Favorite

Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis

By  

Dermatology, Vol. 216, Iss. 3, 2008-01 ,pp. : 260-270

Karger

Access to resources Recommend Favorite